Published in Int J Radiat Oncol Biol Phys on November 01, 2008
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics (2009) 2.38
Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics (2013) 1.38
Stochastic functional data analysis: a diffusion model-based approach. Biometrics (2011) 1.22
Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys (2010) 1.15
The effect of salvage therapy on survival in a longitudinal study with treatment by indication. Stat Med (2010) 1.06
Semiparametric Stochastic Modeling of the Rate Function in Longitudinal Studies. J Am Stat Assoc (2011) 0.87
Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation. Stat Methods Med Res (2014) 0.82
Comparison of methods for estimating the effect of salvage therapy in prostate cancer when treatment is given by indication. Stat Med (2013) 0.78
Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion. Jpn J Clin Oncol (2010) 0.77
Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer. Stat Med (2016) 0.75
Joint partially linear model for longitudinal data with informative drop-outs. Biometrics (2016) 0.75
Random-effects models for longitudinal data. Biometrics (1982) 54.17
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys (1997) 4.58
PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2004) 2.18
Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA (1999) 2.16
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys (2003) 1.65
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer (2007) 1.54
What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice. Int J Radiat Oncol Biol Phys (2003) 1.48
Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys (2002) 1.46
Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol (1997) 1.46
Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol (2005) 1.45
Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.45
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys (2005) 1.42
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys (2004) 1.40
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.39
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys (2005) 1.22
Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer (1999) 1.16
Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys (1997) 1.12
Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.10
Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys (2006) 1.10
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer (1994) 1.07
Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.01
Does age influence the behaviour of localized prostate cancer? BJU Int (2001) 0.96
Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer (1993) 0.92
Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 0.91
Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology (2003) 0.81
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med (2011) 7.46
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol (2008) 4.69
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol (2003) 4.33
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol (2008) 4.11
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol (2002) 3.89
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol (2009) 3.86
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol (2010) 3.59
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 3.41
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Subgroup identification from randomized clinical trial data. Stat Med (2011) 3.22
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
MicroRNA control of muscle development and disease. Curr Opin Cell Biol (2009) 3.04
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
MicroRNAs flex their muscles. Trends Genet (2008) 2.94
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2010) 2.69
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics (2009) 2.38
Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 2.33
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys (2004) 2.17
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Semiparametric modeling of longitudinal measurements and time-to-event data--a two-stage regression calibration approach. Biometrics (2008) 2.05
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
Evidence for mutation showers. Proc Natl Acad Sci U S A (2007) 2.00
Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun (2013) 2.00
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83
Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer (2007) 1.83
Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy: A dosimetric and treatment efficiency analysis. Radiother Oncol (2010) 1.81
Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys (2003) 1.78
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst (2009) 1.75
Image-guided radiotherapy via daily online cone-beam CT substantially reduces margin requirements for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.75
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol (2003) 1.74
Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol (2011) 1.71
A bayesian approach to surrogacy assessment using principal stratification in clinical trials. Biometrics (2009) 1.69
Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.69
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res (2010) 1.67
Research on bell-shaped vibratory angular rate gyro's character of resonator. Sensors (Basel) (2013) 1.66
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.63
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Scene-selective cortical regions in human and nonhuman primates. J Neurosci (2011) 1.62
Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med (2002) 1.62
Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.61
A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics (2002) 1.59
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.58
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys (2006) 1.55
Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols. Int J Radiat Oncol Biol Phys (2005) 1.55
A semi-parametric accelerated failure time cure model. Stat Med (2002) 1.53
Survival analysis using auxiliary variables via non-parametric multiple imputation. Stat Med (2006) 1.53
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.52
Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors. Am J Clin Pathol (2005) 1.52
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
Bis(benzyl-trimethyl-ammonium) tetra-bromidocuprate(II). Acta Crystallogr Sect E Struct Rep Online (2011) 1.52
Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys (2003) 1.52
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49